Business Context and Reporting Period
This Form 8-K reports on the 2016 Annual Meeting of Stockholders held by Akebia Therapeutics, Inc. on June 16, 2016. The filing details the election of directors and the ratification of the independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes
There are no material financial changes reported in this filing. The primary events are the election of two new directors to the Board of Directors for three-year terms expiring in 2019 and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of stockholder voting outcomes.
Important Facts for Investors
- Meeting Date: June 16, 2016.
- Shares Eligible to Vote: 37,765,632 as of the April 18, 2016 record date.
- Director Elections: Anupam Dalal and Maxine Gowen were elected. Both received approximately 21.9 million votes "For," with significant broker non-votes (7,456,735 each) and votes withheld (approx. 3.4 million each).
- Auditor Ratification: Ernst & Young LLP was ratified with 32,887,798 votes "For," 61,878 "Against," and 11,477 abstentions.